Any feedback?
No. of entries
Information on EC 3.4.21.B39 - stratum corneum tryptic enzyme
for references in articles please use BRENDA:EC3.4.21.B39
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Old data from external sources may still be available.
Please check here for current data: EC unknown
Please check here for current data: EC unknown
preliminary BRENDA-supplied EC number
EC Tree 3 Hydrolases
3.4 Acting on peptide bonds (peptidases)
3.4.21 Serine endopeptidases
3.4.21.B39 stratum corneum tryptic enzyme
The enzyme appears in viruses and cellular organisms
- 3.4.21.B39
- klk5
- keratinocytes
-
desquamation
- cathelicidin
- netherton
-
spink5
- rosacea
-
kazal-type
- lekti
- filaggrin
-
lympho-epithelial
-
corneodesmosomes
-
transepidermal
- lymphopoietin
- corneodesmosin
-
kazal
-
desmocollin
-
corneocyte
- medicine
- diagnostics
showSynonyms
kallikrein 5, stratum corneum tryptic enzyme, kallikrein-related peptidase 5, human kallikrein 5, kallikrein-5, klk-l2, kallikrein protein 5, tissue kallikrein 5, more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
hK5
K5
kallikrein 5
kallikrein-like protein 2
KLK5
S01.017
-
-
-
-
SCTE
tissue kallikrein 5
additional information
-
the enzyme belongs to the human kallikrein, KLK, gene family
kallikrein 5
-
-
-
-
KLK5
-
-
tissue kallikrein 5
-
serine protease with trypsin-like activity for Arg at the P1 position
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
proteolytic cleavage of polypeptides
substrate binding pocket contains an Asp residue
proteolytic cleavage of polypeptides
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of peptide bond
hydrolysis of peptide bond
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
272788-46-2
-
9001-01-8
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
LITERATURE
COMMENTARY
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(Tos-Gly-Pro-Arg)2[R110] + H2O
2 Tos-Gly-Pro-Arg + rhodamin110
Substrates: fluorogenic subtrate for thrombin
Products: -
Products: -
?
Abz-APGRVVGGA-Q-N-[2,4-dinitrophenyl]-ethylenediamine + H2O
?
Substrates: -
Products: -
Products: -
?
Ala-Thr-Pro-Lys-Ile-Phe-Asn + H2O
Ala-Thr-Pro-Lys + Ile-Phe-Asn
-
Substrates: moderate cleavage efficiency
Products: -
Products: -
?
Asp-Gly-Asp-Lys-Ile-Ile-Glu + H2O
Asp-Gly-Asp-Lys + Ile-Ile-Glu
-
Substrates: low cleavage efficiency
Products: -
Products: -
?
Asp-Thr-Arg-Ala-Ile-Gly + H2O
Asp-Thr-Arg + Ala-Ile-Gly
-
Substrates: moderate cleavage efficiency
Products: -
Products: -
?
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Leu-Arg + 7-amino-4-methylcoumarin
-
Substrates: -
Products: -
Products: -
?
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
Substrates: -
Products: -
Products: -
?
benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Val-Val-Arg + 7-amino-4-methylcoumarin
-
Substrates: -
Products: -
Products: -
?
Boc-Gln-Ala-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Gln-Ala-Arg + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
Boc-Gln-Arg-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Gln-Arg-Arg + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
Boc-Gln-Gly-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Gln-Gly-Arg + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
Boc-Leu-Arg-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Leu-Arg-Arg + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
Boc-Leu-GLy-Arg-7-amido-4-methylcoumarin + H2O
Boc-Leu-Gly-Arg + 7-amino-4-methylcoumarin
-
Substrates: -
Products: -
Products: -
?
Boc-Leu-Lys-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Leu-Lys-Arg + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
Boc-Phe-Ser-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Phe-Ser-Arg + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
Boc-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O
Boc-Phe-Ser-Arg + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
Boc-Val-Leu-Lys-7-amido-4-methyl-coumarin + H2O
Boc-Val-Leu-Lys + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
Boc-Val-Pro-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Val-Pro-Arg + 7-amino-4-methyl-coumarin
Cbz-L-Pro-Phe-Arg-p-nitroanilide + H2O
Cbz-L-Pro-Phe-Arg + 4-nitroaniline
Substrates: -
Products: -
Products: -
?
D-Ile-Pro-Arg-p-nitroanilide + H2O
D-Ile-Pro-Arg + p-nitroaniline
Substrates: -
Products: -
Products: -
?
defensin-1alpha + H2O
?
Substrates: KLK5 is capable of processing defensin-1alpha and may be important in vaginal host defense
Products: -
Products: -
?
diglutamyl-Gly-Arg-7-amido-4-methylcoumarin + H2O
diglutamyl-Gly-Arg + 7-amino-4-methylcoumarin
-
Substrates: -
Products: -
Products: -
?
diglutamyl-Pro-Phe-Arg-7-amido-4-methylcoumarin + H2O
diglutamyl-Pro-Phe-Arg + 7-amino-4-methylcoumarin
-
Substrates: -
Products: -
Products: -
?
fibrinogen Aalpha chain + H2O
?
-
Substrates: cleavage after Arg348 and Arg407
Products: -
Products: -
?
fibrinogen Bbeta chain + H2O
?
-
Substrates: cleavage after Lys53 and Arg14
Products: -
Products: -
?
FSR-amido-4-methylcoumarin + H2O
FSR + 7-amino-4-methylcoumarin
Substrates: fluorogenic trypsin-like peptide substrate
Products: -
Products: -
?
Gln-Glu-Asp-Lys-Val-Leu-Gly + H2O
Gln-Glu-Asp-Lys + Val-Leu-Gly
-
Substrates: low cleavage efficiency
Products: -
Products: -
?
Gln-Gly-Asp-Lys-Ile-Ile-Asp + H2O
Gln-Gly-Asp-Lys + Ile-Ile-Asp
-
Substrates: low cleavage efficiency
Products: -
Products: -
?
Glu-Thr-Arg-Ile-Ile-Lys + H2O
Glu-Thr-Arg + Ile-Ile-Lys
-
Substrates: moderate cleavage efficiency
Products: -
Products: -
?
H-Pro-Phe-Ser-Arg-7-amido-4-methyl-coumarin + H2O
H-Pro-Phe-Ser-Arg + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
hK3 + H2O
?
-
Substrates: hK5 can inactivate hK3 by subsequent cleavage after activation
Products: -
Products: -
?
human plasminogen + H2O
human plasmin + ?
Substrates: generation of a 29 kDa fragment
Products: -
Products: -
?
Ile-Gln-Ser-Arg-Ile-Val-Gly + H2O
Ile-Gln-Ser-Arg + Ile-Val-Gly
-
Substrates: high cleavage efficiency
Products: -
Products: -
?
Ile-Leu-Ser-Arg-Ile-Val
Ile-Leu-Ser-Arg + Ile-Val
-
Substrates: optimal substrate sequences for KLK5
Products: -
Products: -
?
Ile-Leu-Ser-Arg-Ile-Val-Gly + H2O
Ile-Leu-Ser-Arg + Ile-Val-Gly
-
Substrates: high cleavage efficiency
Products: -
Products: -
?
insulin-like growth factor-binding protein 1 + H2O
insulin-like growth factor-binding protein 1a + insulin-like growth factor-binding protein 1b
-
Substrates: cleavage after Lys137
Products: -
Products: -
?
insulin-like growth factor-binding protein 1 + H2O
insulin-like growth factor-binding protein 4a + insulin-like growth factor-binding protein 4b
-
Substrates: cleavage after Arg170
Products: -
Products: -
?
insulin-like growth factor-binding protein 2 + H2O
insulin-like growth factor-binding protein 2a + insulin-like growth factor-binding protein 2b
-
Substrates: cleavage after Arg164
Products: -
Products: -
?
insulin-like growth factor-binding protein 3 + H2O
insulin-like growth factor-binding protein 3a + insulin-like growth factor-binding protein 3b + insulin-like growth factor-binding protein 3c
-
Substrates: cleavage after Arg158 and Arg206
Products: -
Products: -
?
insulin-like growth factor-binding protein 5 + H2O
insulin-like growth factor-binding protein 5a + insulin-like growth factor-binding protein 5b + insulin-like growth factor-binding protein 5c
-
Substrates: cleavage after Arg123 and Arg212
Products: -
Products: -
?
insulin-like growth factor-binding protein-3 + H2O
?
-
Substrates: -
Products: -
Products: -
?
kallikrein 7 + H2O
?
-
Substrates: Gln-Gly-Asp-Lys-/-Ile-Ile. KLK7 is activated at a low rate
Products: -
Products: -
?
kininogen + H2O
?
-
Substrates: cleavage after Arg222, Arg252 and Arg374
Products: -
Products: -
?
L-Ile-Pro-Arg-4-nitroanilide + H2O
L-Ile-Pro-Arg + 4-nitroaniline
Substrates: -
Products: -
Products: -
?
L-Pro-Phe-Arg-7-amido-4-methylcoumarin + H2O
L-Pro-Phe-Arg + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
pro-hK2 + H2O
hK2 + ?
-
Substrates: hK5 can activate hK2 through cleavage after Lys137
Products: -
Products: -
?
pro-hK3 + H2O
hK3 + ?
-
Substrates: hK5 can activate hK3 through cleavage after Arg85 and Lys182
Products: -
Products: -
?
Pro-Phe-Ser-Arg-7-amido-4-methyl-coumarin + H2O
Pro-Phe-Ser-Arg + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
pro-[stratum corneum chymotryptic enzyme] + H2O
stratum corneum chymotryptic enzyme + ?
-
Substrates: stratum corneum tryptic enzyme activates stratum corneum chymotryptic enzyme through cleavage of the 31 kDa proenzyme resulting in the mature 28 kDa enzyme
Products: -
Products: -
?
Ser-Ser-Ser-Arg-Ile-Ile-Asn + H2O
Ser-Ser-Ser-Arg + Ile-Ile-Asn
-
Substrates: moderate cleavage efficiency
Products: -
Products: -
?
tert-butyloxycarbonyl-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O
tert-butyloxycarbonyl-Phe-Ser-Arg + 7-amino-4-methylcoumarin
-
Substrates: -
Products: -
Products: -
?
Tos-Gly-Pro-Arg-7-amido-4-methyl-coumarin + H2O
Tos-Gly-Pro-Arg + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
Tos-Gly-Pro-Lys-7-amido-4-methylcoumarin + H2O
Tos-Gly-Pro-Lys + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
tosyl-Gly-Pro-Arg-7-amido-4-methylcoumarin + H2O
tosyl-Gly-Pro-Arg + 7-amino-4-methylcoumarin
Substrates: -
Products: -
Products: -
?
VPR-amido-4-methylcoumarin + H2O
VPR + 7-amino-4-methylcoumarin
Substrates: fluorogenic trypsin-like peptide substrate
Products: -
Products: -
?
Z-Gly-Gly-Arg-7-amido-4-methyl-coumarin + H2O
Z-Gly-Gly-Arg + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
Boc-Val-Pro-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Val-Pro-Arg + 7-amino-4-methyl-coumarin
-
Substrates: -
Products: -
Products: -
?
Boc-Val-Pro-Arg-7-amido-4-methyl-coumarin + H2O
Boc-Val-Pro-Arg + 7-amino-4-methyl-coumarin
Substrates: -
Products: -
Products: -
?
polypeptide + H2O
peptides
Substrates: enzyme is regulated by binding to protease inhibitors
Products: -
Products: -
?
proform filaggrin + H2O
mature filaggrin + ?
Substrates: the enzyme and profilaggrin co-localize in the stratum granulosum in human epidermis. The enzyme interacts with its substrates in granular cells
Products: -
Products: -
?
proform filaggrin + H2O
mature filaggrin + ?
Substrates: the filaggrin linker domain is the site for processing, recombinant human 53-kDa filaggrin protein
Products: 41-kDa filaggrin fragment
Products: 41-kDa filaggrin fragment
?
tert-butyloxycarbonyl-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O
?
-
Substrates: best substrate
Products: -
Products: -
?
tert-butyloxycarbonyl-Phe-Ser-Arg-7-amido-4-methylcoumarin + H2O
?
Substrates: best substrate
Products: -
Products: -
?
tert-butyloxycarbonyl-Val-Pro-Arg-7-amido-4-methylcoumarin + H2O
?
-
Substrates: best substrate
Products: -
Products: -
?
tert-butyloxycarbonyl-Val-Pro-Arg-7-amido-4-methylcoumarin + H2O
?
Substrates: best substrate
Products: -
Products: -
?
additional information
?
-
Substrates: no activity with AAPF-amido-4-methylcoumarin
Products: -
Products: -
?
additional information
?
-
-
Substrates: no activity with AAPF-amido-4-methylcoumarin
Products: -
Products: -
?
additional information
?
-
Substrates: enzyme shows trypsin-like but not chymotrypsin-like activity
Products: -
Products: -
?
additional information
?
-
-
Substrates: enzyme shows trypsin-like but not chymotrypsin-like activity
Products: -
Products: -
?
additional information
?
-
Substrates: involved in ovarian cancer
Products: -
Products: -
?
additional information
?
-
Substrates: regulation by steroid homones
Products: -
Products: -
?
additional information
?
-
Substrates: the enzyme is differentially expressed at the mRNA and protein level in diverse malignancies including cancer
Products: -
Products: -
?
additional information
?
-
-
Substrates: the enzyme is differentially expressed at the mRNA and protein level in diverse malignancies including cancer
Products: -
Products: -
?
additional information
?
-
-
Substrates: KLK5 plays a central role in skin desquamation as an initiating activating enzyme in proteolytic cascades formed by kallikreins
Products: -
Products: -
?
additional information
?
-
-
Substrates: KLK5 activates itself efficiently at the cleavage site Ser-Ser-Ser-Arg-/-Ile-Ile. KLK5 is able to induce signaling events via proteinase-activated receptor-2. Strong preference for P1-Arg over Lys (Lys is accepted by the S1 pocket to some extent) and the complete exclusion of chymotrypsin-specific substrates with a Phe or Tyr side chain in P1 position. Preference for Ala and Lys at P2, preference for Gly in P4
Products: -
Products: -
?
additional information
?
-
Substrates: displays a trypsin-like specificity with strong preference for Arg at position P1. The S1 pocket of hK5 is very specific for P1-Arg side chains. Thr, Asn, Gln, and Ile are tolerated at position P1, whereas the residual amino acids, in particular with large aromatic side chains and Lys, are hardly accepted. Ser is slightly preferred over Asn, Thr, and Ala at position P2, whereas among all other residues only Arg and Tyr are rejected. Most amino acids, in particular Met, Phe, and Tyr but not Asp, are accepted in position P3. An unusual preference for Gly followed by Tyr, Val, and Pro is observed at position P4
Products: -
Products: -
?
additional information
?
-
-
Substrates: no activity with Abz-KLYSSKQ-EDDnp
Products: -
Products: -
?
additional information
?
-
Substrates: no activity with peptides CPGRVVGGC, and QVEPKKCPGRVVGGCVAHPHS
Products: -
Products: -
?
additional information
?
-
-
Substrates: no activity with tert-butyloxycarbonyl-Val-Leu-Lys-7-amido-4-methylcoumarin, tert-butyloxycarbonyl-Glu-Lys-Lys-7-amido-4-methylcoumarin, acetyl-Ile-Glu-Thr-Asp-7-amido-4-methylcoumarin, succinyl-Ala-Ala-Pro-Phe-7-amido-4-methylcoumarin, succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin, casein, laminin, and single-chain tissue-type plasminogen activator
Products: -
Products: -
?
additional information
?
-
Substrates: unregulated KLK5 directly activates proteinase-activated receptor 2 and induces nuclear factor kappaB-mediated overexpression of TSLP, intercellular adhesion molecule 1, tumor necrosis factor alpha, and IL8
Products: -
Products: -
?
additional information
?
-
-
Substrates: unregulated KLK5 directly activates proteinase-activated receptor 2 and induces nuclear factor kappaB-mediated overexpression of TSLP, intercellular adhesion molecule 1, tumor necrosis factor alpha, and IL8
Products: -
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
LITERATURE
COMMENTARY
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
defensin-1alpha + H2O
?
Substrates: KLK5 is capable of processing defensin-1alpha and may be important in vaginal host defense
Products: -
Products: -
?
proform filaggrin + H2O
mature filaggrin + ?
Substrates: the enzyme and profilaggrin co-localize in the stratum granulosum in human epidermis. The enzyme interacts with its substrates in granular cells
Products: -
Products: -
?
polypeptide + H2O
peptides
Substrates: enzyme is regulated by binding to protease inhibitors
Products: -
Products: -
?
additional information
?
-
Substrates: involved in ovarian cancer
Products: -
Products: -
?
additional information
?
-
Substrates: regulation by steroid homones
Products: -
Products: -
?
additional information
?
-
Substrates: the enzyme is differentially expressed at the mRNA and protein level in diverse malignancies including cancer
Products: -
Products: -
?
additional information
?
-
-
Substrates: the enzyme is differentially expressed at the mRNA and protein level in diverse malignancies including cancer
Products: -
Products: -
?
additional information
?
-
-
Substrates: KLK5 plays a central role in skin desquamation as an initiating activating enzyme in proteolytic cascades formed by kallikreins
Products: -
Products: -
?
additional information
?
-
Substrates: unregulated KLK5 directly activates proteinase-activated receptor 2 and induces nuclear factor kappaB-mediated overexpression of TSLP, intercellular adhesion molecule 1, tumor necrosis factor alpha, and IL8
Products: -
Products: -
?
additional information
?
-
-
Substrates: unregulated KLK5 directly activates proteinase-activated receptor 2 and induces nuclear factor kappaB-mediated overexpression of TSLP, intercellular adhesion molecule 1, tumor necrosis factor alpha, and IL8
Products: -
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(S)-methyl-1-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanoyl) pyrrolidine-2-carboxylate
-
(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-methylbutanoate
-
(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-phenylpropanoate
-
4-[(3R)-1-hydroxy-7-(trifluoromethyl)-3,4-dihydro-1H-2,1-benzoxaborinin-3-yl]-2-[(pyridin-3-yl)methoxy]benzene-1-carboximidamide
inhibitor based on benzoxaborin, shows good selectivity against both protease and nonprotease targets and has good stability and solubility
brazilin
natural compound derived from the wood of Caesalpinia sappan, the phenolic moiety of Brazilin binds in the S1-pocket of KLK5 and forms a H-bond with S195
KLK5
cyclic peptide inhibitor, uses amino acids Gly, Cys, Thr, Arg, Gln, Tyr, Pro, Cys
N-(4-carbamimidoyl-2-fluorophenyl)-2-hydroxybenzamide
pIC50: 5.6, compared to pIC50 for KLK1: 5.5
N-(4-carbamimidoyl-2-methylphenyl)-2-hydroxybenzamide
pIC50: 4.9, compared to pIC50 for KLK1: 5.3
N-(4-carbamimidoyl-3-chlorophenyl)-2-hydroxy-3-methoxybenzamide
pIC50: 5.0, compared to pIC50 for KLK1: 5.9
N-(4-carbamimidoyl-3-fluorophenyl)-2-hydroxy-3-methoxybenzamide
pIC50: 6.0, compared to pIC50 for KLK1: 6.6
N-(4-carbamimidoyl-3-fluorophenyl)-2-hydroxybenzamide
pIC50: 4.7, compared to pIC50 for KLK1: 4.9
N-(4-carbamimidoylphenyl)-1-methyl-1H-benzimidazole-2-carboxamide
PIC50: 3.7, compared to pIC50 for KLK1: 3.7
N-(4-carbamimidoylphenyl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
pIC50: 3.3, compared to pIC50 for KLK1: 3.3
N-(4-carbamimidoylphenyl)-2,3-dihydroxybenzamide
pIC50: 5.6, compared to pIC50 for KLK1: 5.4
N-(4-carbamimidoylphenyl)-2-hydroxy-3-methoxybenzamide
pIC50: 6.3, compared to pIC50 for KLK1: 6.5
N-(4-carbamimidoylphenyl)-2-hydroxy-3-methylbenzamide
pIC50: 5.1, compared to pIC50 for KLK1: 5.5
N-(4-carbamimidoylphenyl)-2-hydroxybenzamide
PIC50: 5.2, compared to pIC50 for KLK1: 4.9
N-(4-carbamimidoylphenyl)-2-oxopiperidine-3-carboxamide
pIC50: 3.3, compared to pIC50 for KLK1: 3.3
N-(4-carbamimidoylphenyl)-2-oxotetrahydropyrimidine-1(2H)-carboxamide
pIC50: 3.2, compared to pIC50 for KLK1: 3.2
N-(4-carbamimidoylphenyl)-3-chloro-2-hydroxybenzamide
pIC50: 5.6, compared to pIC50 for KLK1: 6.2
N-(4-carbamimidoylphenyl)-3-ethoxy-2-hydroxybenzamide
pIC50: 5.3, compared to pIC50 for KLK1: 6.9
SPINK9
-
i.e. serine protease inhibitor Kazal type 9, KLK5-specific inhibitor, KLK5 degradation of fibrinogen was totally inhibited by SPINK9
-
SPINK9
-
i.e. LEKTI-2. Inhibits KLK5 but not KLK7, 14 or other serine proteases tested including trypsin, plasmin and thrombin. LEKTI-2 contributes to the regulation of the desquamation process in human skin by specifically inhibiting KLK5
-
Zn2+
-
75% inhibition at 12 nM, 93.5% inhibition at 60 nM, 97.5% inhibition at 120 nM, complete inhibition at 1200 nM
Zn2+
non-competitive inhibition, the enzyme activity is restored by addition of EDTA showing reversibility
additional information
not inhibited by lympho-epithelial Kazal type inhibitor fragment D1
-
additional information
no significant effect on enzyme activity by chondroitin
-
additional information
identification and design of KLK5 inhibitors with encouraging potency and efficiency, with 10-100fold selectivity over the key liability target KLK1
-
additional information
-
not inhibited by soybean trypsin inhibitor, benzamidine, pepstatin, EDTA, and chymostatin
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
additional information
no significant effect on enzyme activity by chondroitin
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Clinical significance of kallikrein 5 as a novel prognostic biomarker in gastric adenocarcinoma.
Adenocarcinoma of Lung
PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.
Breast Neoplasms
Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions.
Breast Neoplasms
Evaluation of Kallikrein-related Peptidase 5 Expression and its Significance for Breast Cancer Patients: Association with Kallikrein-related Peptidase 7 Expression.
Breast Neoplasms
Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer.
Breast Neoplasms
Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model.
Breast Neoplasms
The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation.
Carcinogenesis
Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis.
Carcinoma
Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.
Carcinoma
Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis.
Carcinoma
Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma.
Carcinoma
Kallikrein-related Peptidase 5 (KLK5) Expression and Distribution in Canine Cutaneous Squamous Cell Carcinoma.
Carcinoma
The Co-Expression of Kallikrein 5 and Kallikrein 7 Associates with Poor Survival in Non-HPV Oral Squamous-Cell Carcinoma.
Carcinoma, Squamous Cell
Kallikrein-related Peptidase 5 (KLK5) Expression and Distribution in Canine Cutaneous Squamous Cell Carcinoma.
Chronic Urticaria
Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.
Colitis
Glutathione peroxidase 2 and aquaporin 8 as new markers for colonic inflammation in experimental colitis and inflammatory bowel diseases: an important role for H2O2?
Dermatitis
Increase in pruritogenic kallikrein 5 in the skin of NC mice with chronic dermatitis.
Dermatitis
Skin pH Is the Master Switch of Kallikrein 5-Mediated Skin Barrier Destruction in a Murine Atopic Dermatitis Model.
Eczema
Transcriptional gene silencing of kallikrein 5 and kallikrein 7 using siRNA prevents epithelial cell detachment induced by alkaline shock in an in vitro model of eczema.
Eosinophilic Esophagitis
Functional role of kallikrein 5 and proteinase-activated receptor 2 in eosinophilic esophagitis.
Influenza, Human
Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.
Influenza, Human
Kallikrein-related peptidase 5 and seasonal influenza viruses, limitations of the experimental models for activating proteases.
Influenza, Human
Kallikrein-Related Peptidase 5 Contributes to H3N2 Influenza Virus Infection in Human Lungs.
Mycosis Fungoides
Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression.
Neoplasms
Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome.
Neoplasms
Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression.
Neoplasms
Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7.
Neoplasms
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Neoplasms
Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
Neoplasms
Human kallikrein 3 (prostate specific antigen) and human kallikrein 5 expression in salivary gland tumors.
Neoplasms
Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7.
Neoplasms
Kallikrein 5 overexpression is associated with poor prognosis in uterine cervical cancer.
Neoplasms
Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer.
Neoplasms
Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies.
Neoplasms
PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.
Neoplasms
Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker.
Neoplasms
Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5.
Netherton Syndrome
A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
Netherton Syndrome
Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.
Netherton Syndrome
Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome.
Netherton Syndrome
Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
Netherton Syndrome
Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.
Netherton Syndrome
Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.
Netherton Syndrome
Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.
Netherton Syndrome
SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Netherton Syndrome
Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.
Netherton Syndrome
Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
Ovarian Neoplasms
Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome.
Ovarian Neoplasms
Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer.
Ovarian Neoplasms
Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.
Ovarian Neoplasms
Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis.
Ovarian Neoplasms
Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.
Ovarian Neoplasms
The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids.
Prostatic Neoplasms
Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer.
Prostatic Neoplasms
Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression.
Pruritus
Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.
Pruritus
Mechanisms of itching in mycosis fungoides: grade of itching correlates with eosinophil infiltration and kallikrein 5 expression.
Rosacea
A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages.
Rosacea
Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.
Rosacea
Citron Essential Oils Alleviate the Mediators Related to Rosacea Pathophysiology in Epidermal Keratinocytes.
Rosacea
Coptis chinensis Franch Directly Inhibits Proteolytic Activation of Kallikrein 5 and Cathelicidin Associated with Rosacea in Epidermal Keratinocytes.
Rosacea
Doxycycline Indirectly Inhibits Proteolytic Activation of Tryptic Kallikrein-Related Peptidases and Activation of Cathelicidin.
Rosacea
Hyaluronan Oligosaccharides Improve Rosacea-Like Phenotype through Anti-Inflammatory and Epidermal Barrier-Improving Effects.
Rosacea
Kallikrein 5-Mediated Inflammation in Rosacea: Clinically Relevant Correlations with Acute and Chronic Manifestations in Rosacea and How Individual Treatments May Provide Therapeutic Benefit.
Rosacea
Multifunctional Serine Protease Inhibitor-Coated Water-Soluble Gold Nanoparticles as a Novel Targeted Approach for the Treatment of Inflammatory Skin Diseases.
Rosacea
TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes.
Skin Diseases
Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.
Skin Diseases
Hyaluronan Oligosaccharides Improve Rosacea-Like Phenotype through Anti-Inflammatory and Epidermal Barrier-Improving Effects.
Skin Diseases
Multifunctional Serine Protease Inhibitor-Coated Water-Soluble Gold Nanoparticles as a Novel Targeted Approach for the Treatment of Inflammatory Skin Diseases.
Skin Diseases
Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses.
Squamous Cell Carcinoma of Head and Neck
Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis.
Squamous Cell Carcinoma of Head and Neck
Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma.
Triple Negative Breast Neoplasms
Human kallikrein 5 as a novel prognostic biomarker for triple-negative breast cancer: tissue expression analysis and relationship with disease course.
Ureteral Obstruction
MiR-382 targeting of kallikrein 5 contributes to renal inner medullary interstitial fibrosis.
Urticaria
Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.
Uterine Cervical Neoplasms
Kallikrein 5 overexpression is associated with poor prognosis in uterine cervical cancer.
Virus Diseases
Kallikrein-Related Peptidase 5 Contributes to H3N2 Influenza Virus Infection in Human Lungs.
Vulvodynia
Decreased concentration of protease inhibitors: possible contributors to allodynia and hyperalgesia in women with vestibulodynia.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.05
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.13
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.11
benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.61
Boc-Gln-Ala-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
1.41
Boc-Gln-Arg-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.57
Boc-Gln-Gly-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.48
Boc-Leu-Arg-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.15
Boc-Leu-GLy-Arg-7-amido-4-methylcoumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
1.01
Boc-Leu-Lys-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.19
Boc-Phe-Ser-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.64
Boc-Val-Leu-Lys-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.02
Boc-Val-Pro-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.03
diglutamyl-Gly-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.03
diglutamyl-Pro-Phe-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
1.77
H-Pro-Phe-Ser-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
1.69
Tos-Gly-Pro-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.31
Z-Gly-Gly-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.05
benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.13
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.11
benzyloxycarbonyl-Val-Val-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
1.78
Boc-Gln-Ala-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.41
Boc-Gln-Arg-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.18
Boc-Gln-Gly-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.31
Boc-Leu-Arg-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.07
Boc-Leu-GLy-Arg-7-amido-4-methylcoumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.82
Boc-Leu-Lys-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
2.83
Boc-Phe-Ser-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.08
Boc-Val-Leu-Lys-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
3.28
Boc-Val-Pro-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.03
diglutamyl-Gly-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.03
diglutamyl-Pro-Phe-Arg-7-amido-4-methylcoumarin
-
in 0.1 M Tris-HCl buffer (pH 8.0)
0.47
H-Pro-Phe-Ser-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.35
Tos-Gly-Pro-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
0.04
Z-Gly-Gly-Arg-7-amido-4-methyl-coumarin
-
100 mM phosphate, 0.01% Tween 20, pH 8.0, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.00013
(S)-methyl-1-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanoyl) pyrrolidine-2-carboxylate
pH 7.5, 37°C
0.00013
(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-methylbutanoate
pH 7.5, 37°C
0.00012
(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-phenylpropanoate
pH 7.5, 37°C
0.0244
8,8'-paepalantine dimer
-
pH and temperature not specified in the publication
0.0064
brazilin
pH not specified in the publication, temperature not specified in the publication
0.0017
leupeptin
at 25°C in 0.2 M NaCl, 0.1 M Tris-HCl (pH 8.0), and 9% (w/v) Me2SO
0.002
Zn2+
in 150 mM NaCl, 20 mM HEPES, 0.04 mM imidazole, 0.005% (v/v) Tween 20, at pH 8.0
0.008
Zn2+
in 150 mM NaCl, 20 mM HEPES, 0.04 mM imidazole, 0.005% (v/v) Tween 20, at pH 7.0
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.000122
(S)-methyl-1-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanoyl) pyrrolidine-2-carboxylate
Homo sapiens
pH 7.5, 37°C
0.000115
(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-methylbutanoate
Homo sapiens
pH 7.5, 37°C
0.000112
(S)-methyl-2-((3'S,4'S)-4'-(tert-butoxycarbonylamino)-3'-hydroxy-5'-phenylpentanamido)-3-phenylpropanoate
Homo sapiens
pH 7.5, 37°C
0.0729
8,8'-paepalantine dimer
Homo sapiens
-
pH and temperature not specified in the publication
0.05
brazilin
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
37
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
brenda
-
SwissProt
brenda
can be processed to active enzyme from inactive precursor by trypsin
SwissProt
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
level of KLK 5 peaks around 4 days post ovulation
brenda
gene overexpression in a subset of more aggressive ovarian tumors
brenda
-
decreased immunohistochemical expression compared to normal cells
brenda
KLK5 peaks slightly at mid-cycle and shows a major peak at day 25 of menstrual cycle
brenda
-
expression levels of KLK5 and KLK7 in benign breast tissues and metastases, and the relationship between KLK5 and KLK7 expression and and clinicopathological factors. mRNA levels of KLK5 and KLK7 in normal breast tissues, benign breast tissues, primary tumors, and lymph node metastases, overview. mRNA levels of KLK5 and KLK7 are both downregulated in breast cancers relative to normal and benign tissues, and downregulated in metastases compared to primary cancers
brenda
-
expression levels of KLK5 and KLK7 in benign breast tissues and metastases, and the relationship between KLK5 and KLK7 expression and and clinicopathological factors. mRNA levels of KLK5 and KLK7 in normal breast tissues, benign breast tissues, primary tumors, and lymph node metastases, overview. mRNA levels of KLK5 and KLK7 are both downregulated in breast cancers relative to normal and benign tissues, and downregulated in metastases compared to primary cancers
brenda
-
kallikreins 5, 7, 8, and 10 are abundantly expressed in human oral squamous cell carcinoma and may be implicated in malignant progression
brenda
specimens from patients with benign prostatic hyperplasia (BPH) show higher levels of KLK5 mRNA expression than those from patients with prostate cancer
brenda
-
KLK5 is highly expressed in the upper stratum granulosum, stratum corneum, hair follicles and sweat glands
brenda
kallikrein-related peptidase 5 is a major serine protease found in the skin, which is secreted from lamellar granules following its expression in the stratum granulosum and activated in the extracellular space of the stratum corneum
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
-
cytoplasmic expression of KLK5 in cutaneous squamous cell carcinoma
brenda
the enzyme is secreted from lamellar granules in the skin and activated in the extracellular space of the stratum corneum
-
brenda
Highest Expressing Human Cell Lines
Cell Line LinksPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
metabolism
KLK5 is part of an original biological cascade in which unregulated KLK5 directly activates proteinase-activated receptor 2 and induces nuclear factor kappaB-mediated overexpression of TSLP, intercellular adhesion molecule 1, tumor necrosis factor alpha, and IL8. This proinflammatory and proallergic pathway is independent of the primary epithelial failure and is activated under basal conditions in NS keratinocytes
physiological function
additional information
potential role of endogenous KLK5 expression in supporting CaP cells to cope with the cytostatic phenomena induced by chemotherapeutic agents practiced in standard first-line CaP chemotherapy
malfunction
-
KLK5 and KLK7 are underexpressed in parallel, potentially with the same regulation pathways, in breast malignancies, which might contribute to the carcinogenesis and development of breast cancer
malfunction
kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome, phenotype, overview
malfunction
-
knockdown of kallikrein-5 expression reduces processing of desmoglein 1
malfunction
KLK5 knockdown in normal cultured human epidermal keratinocytes results in higher levels of profilaggrin
malfunction
Netherton syndrome is a rare and debilitating severe autosomal recessive genetic skin disease with high mortality rates particularly in neonates. NS is caused by loss-of-function SPINK5 mutations leading to unregulated kallikrein 5 and kallikrein 7 activity
malfunction
the role of skin pH in the pathogenesis of atopic dermatitis is explored using the NC/Tnd murine atopic dermatitis model. Alterations in skin pH directly modulate kallikrein 5 activity leading to skin barrier dysfunction, itch, and dermatitis via the protease-activated receptor 2 thymic stromal lymphopoietin pathway
physiological function
-
kallikrein 5 is implicated in the destruction of corneodesomosomes
physiological function
-
kallikrein-5 promotes metastatic dissemination of oral squamous cell carcinoma cells by promoting loss of junctional integrity through cleavage of desmoglein 1
physiological function
the enzyme plays a role in skin desquamation. KLK5 activates proteinase-activated receptor, which is involved in itching
physiological function
knockdown of KLK5 inhibits lung adenocarcinoma cancer cell invasion and proliferation. Down-modulation of either PRSS3 or KLK5 expression in lung adenocarcinoma cells results in a robust transcriptional response
physiological function
KLK 5 degrades the basal side of the bronchial epithelium. Knockdown of endogenous KLK5 in 16HBE14o-cells accelerates wound healing repair after injury, and exogenous KLK5 addition delays the closure repair
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). K1KB5_MOUSE
261
0
28748
Swiss-Prot
Mitochondrion (Reliability: 3)
KLK5_HUMAN
293
0
32020
Swiss-Prot
other Location (Reliability: 2)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
30000
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
monomer
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
glycoprotein
proteolytic modification
can be processed to active enzyme from inactive precursor by trypsin
glycoprotein
4 potential N-glycosylation sites at amino acid residues positions 69, 173, 208, and 252
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
crystallized in complex with leupeptin, sitting drop vapour diffusion method with 0.2 M ammonium sulfate, 0.1 M Mes (pH 5.6) and 30% (w/v) PEG monomethyl ether 500
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
enzyme knockout in NHEK cells using KLK5 shRNA expressing vectors
additional information
-
enzyme knockout in NHEK cells using KLK5 shRNA expressing vectors
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANIC SOLVENT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
heparin-Sepharose column chromatography and benzamidine-Sepharose column chromatography
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
cloned from a keratinocyte library, DNA sequence determination and analysis, expression in CHO-K1 cells via infection with Semliki Forest Virus system
cloned from RNA isolated from HaCaT cells, expression as His-tagged enzyme in Escherichia coli BL21(DE3)
DNA sequence determination and analysis, expression in CHO-CCL-61 cells, in Escherichia coli, and in Pichia pastoris
expression of residues Asn30-Ser293 and a C-terminal His-tag, in CHO cell
gene KLK5, genetic organization and structure of the kallikrein gene family, clustered on chromosome 19q13.3-q13.4
gene KLK5, located at the chromosomal locus 19q13.3-q13.4, quantitative real-time PCR expression analysis, 10 transcription factors as potential regulators were found on the control regions of both KLK5 and KLK7
-
overexpression in OV-MZ-6 cancer cell line inoculated into the peritoneal cavity of nude mice promotes tumor growth in mice
-
recombinant KLK5 protein is generated from a recombinant baculovirus using the BAC-TO-BAC system (pFastBac_hKLK5_6His-Q-FLAG) expressed in 5L of Spodoptera frugiperda Super 9 insect cells
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
10 transcription factors as potential regulators are found on the control regions of both KLK5 and KLK7
-
expression of kallikrein 5 is higher in oral squamous cell carcinoma cell compared to pre-malignant cells
-
KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone
the enzyme is upregulated in some types of cancers, mainly prostate and ovarian cancers
the expression of KLK5 is increased in the epidermis of patients with atopic dermatitis and its activity increases in atopic dermatitis-like lesions
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
diagnostics
medicine
diagnostics
KLK5 is a promising biomarker for prostate cancer diagnosis and prognosis
diagnostics
the expression level of human kallikrein 5 in tumor stromal cells is a promising biomarker for poor prognosis in triple-negative breast cancer. Patients with high histological grade are more prone to distal metastasis and aggressive tumor progression
medicine
regulation by protease inhibitors may have potential clinical applications
medicine
KLK5 mRNA, analyzed by quantitative PCR in prostate needle biopsies, could be an independent biomarker for the differential diagnosis and prognosis in prostate cancer
medicine
human kallikrein 5 is a potential target for the treatment of skin inflammation and cancer
medicine
elevated KLK5 expression is prognostic for poor outcome for patients with lung adenocarcinoma, and genetic targeting of KLK5 reduces lung adenocarcinoma cell invasiveness and proliferation. Elevated or reduced expression of PRSS3/mesotrypsin knockdown leads to similar effects
medicine
-
in cutaneous squamous cell carcinoma, tumour cells at the deep margin, as well as those in the centre of keratin pearls, display cytoplasmic expression of KLK5 and some of them also express vimentin
medicine
KLK5 degrades the basal layer formed by culture of primary bronchial epithelial cells from chronic obstructive pulmonary disease (COPD) or non-COPD patients and reduces BEAS-2B cell adherence to the extracellular matrix
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Boeckmann, B.; Bairoch, A.; Apweiler, R.; Blatter, M.C.; Estreicher, A.; Gasteiger, E.; Martin M.J.; Michoud, K.; O'Donovan, C.; Phan, I.; Pilbout, S.; Schneider, M.
The SWISS-PROT protein knowledgebase and its supplement TrEMBL
Nucleic Acids Res.
31
365-370
2003
Homo sapiens (Q9Y337), Mus musculus (P15945)
brenda
Yousef, G.M.; Diamandis, E.P.
The new human tissue kallikrein gene family: structure, function, and association to disease
Endocr. Rev.
22
184-204
2001
Homo sapiens (Q9Y337)
brenda
Brattsand, M.; Egelrud, T.
Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation
J. Biol. Chem.
274
30033-30040
1999
Homo sapiens (Q9Y337), Homo sapiens
brenda
Ekholm, I.E.; Brattsand, M.; Egelrud, T.
Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process?
J. Invest. Dermatol.
114
56-63
2000
Homo sapiens (Q9Y337), Homo sapiens
brenda
Yousef, G.M.; Kapadia, C.; Polymeris, M.E.; Borgono, C.; Hutchinson, S.; Wasney, G.A.; Soosaipillai, A.; Diamandis, E.P.
The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids
Biochim. Biophys. Acta
1628
88-96
2003
Homo sapiens (Q9Y337), Homo sapiens
brenda
Prezas, P.; Arlt, M.J.; Viktorov, P.; Soosaipillai, A.; Holzscheiter, L.; Schmitt, M.; Talieri, M.; Diamandis, E.P.; Krueger, A.; Magdolen, V.
Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells
Biol. Chem.
387
807-811
2006
Homo sapiens
brenda
Caubet, C.; Jonca, N.; Brattsand, M.; Guerrin, M.; Bernard, D.; Schmidt, R.; Egelrud, T.; Simon, M.; Serre, G.
Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7
J. Invest. Dermatol.
122
1235-1244
2004
Homo sapiens
brenda
Michael, I.P.; Sotiropoulou, G.; Pampalakis, G.; Magklara, A.; Ghosh, M.; Wasney, G.; Diamandis, E.P.
Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression
J. Biol. Chem.
280
14628-14635
2005
Homo sapiens
brenda
Michael, I.P.; Pampalakis, G.; Mikolajczyk, S.D.; Malm, J.; Sotiropoulou, G.; Diamandis, E.P.
Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression
J. Biol. Chem.
281
12743-12750
2006
Homo sapiens
brenda
Komatsu, N.; Tsai, B.; Sidiropoulos, M.; Saijoh, K.; Levesque, M.A.; Takehara, K.; Diamandis, E.P.
Quantification of eight tissue kallikreins in the Stratum corneum and sweat
J. Invest. Dermatol.
126
925-929
2006
Homo sapiens
brenda
Kurlender, L.; Yousef, G.M.; Memari, N.; Robb, J.D.; Michael, I.P.; Borgono, C.; Katsaros, D.; Stephan, C.; Jung, K.; Diamandis, E.P.
Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer
Tumour Biol.
25
149-156
2004
Homo sapiens
brenda
Yousef, G.M.; White, N.M.; Kurlender, L.; Michael, I.; Memari, N.; Robb, J.D.; Katsaros, D.; Stephan, C.; Jung, K.; Diamandis, E.P.
The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer
Tumour Biol.
25
221-227
2005
Homo sapiens
brenda
Petraki, C.D.; Gregorakis, A.K.; Vaslamatzis, M.M.; Papanastasiou, P.A.; Yousef, G.M.; Levesque, M.A.; Diamandis, E.P.
Prognostic Implications of the Immunohistochemical Expression of Human Kallikreins 5, 6, 10 and 11 in Renal Cell Carcinoma
Tumour Biol.
27
1-7
2006
Homo sapiens
brenda
Shinoda, Y.; Kozaki, K.; Imoto, I.; Obara, W.; Tsuda, H.; Mizutani, Y.; Shuin, T.; Fujioka, T.; Miki, T.; Inazawa, J.
Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells
Cancer Sci.
98
1078-1086
2007
Homo sapiens
brenda
Voegeli, R.; Rawlings, A.V.; Doppler, S.; Heiland, J.; Schreier, T.
Profiling of serine protease activities in human stratum corneum and detection of a stratum corneum tryptase-like enzyme
Int. J. Cosmet. Sci.
29
191-200
2007
Homo sapiens
brenda
Debela, M.; Magdolen, V.; Schechter, N.; Valachova, M.; Lottspeich, F.; Craik, C.S.; Choe, Y.; Bode, W.; Goettig, P.
Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences
J. Biol. Chem.
281
25678-25688
2006
Homo sapiens (Q9Y337)
brenda
Debela, M.; Goettig, P.; Magdolen, V.; Huber, R.; Schechter, N.M.; Bode, W.
Structural basis of the zinc inhibition of human tissue kallikrein 5
J. Mol. Biol.
373
1017-1031
2007
Homo sapiens (Q9Y337), Homo sapiens
brenda
Deraison, C.; Bonnart, C.; Lopez, F.; Besson, C.; Robinson, R.; Jayakumar, A.; Wagberg, F.; Brattsand, M.; Hachem, J.P.; Leonardsson, G.; Hovnanian, A.
LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction
Mol. Biol. Cell
18
3607-3619
2007
Homo sapiens (Q9Y337)
brenda
Rajapakse, S.; Ogiwara, K.; Yamano, N.; Kimura, A.; Hirata, K.; Takahashi, S.; Takahashi, T.
Characterization of mouse tissue kallikrein 5
Zool. Sci.
23
963-968
2006
Mus musculus
brenda
Shaw, J.L.; Petraki, C.; Watson, C.; Bocking, A.; Diamandis, E.P.
Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense
Biol. Chem.
389
1513-1522
2008
Homo sapiens (Q9Y337)
brenda
Debela, M.; Beaufort, N.; Magdolen, V.; Schechter, N.M.; Craik, C.S.; Schmitt, M.; Bode, W.; Goettig, P.
Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7
Biol. Chem.
389
623-632
2008
Homo sapiens
brenda
Korbakis, D.; Gregorakis, A.K.; Scorilas, A.
Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker
Clin. Chem.
55
904-913
2009
Homo sapiens (Q9Y337), Homo sapiens
brenda
Pettus, J.R.; Johnson, J.J.; Shi, Z.; Davis, J.W.; Koblinski, J.; Ghosh, S.; Liu, Y.; Ravosa, M.J.; Frazier, S.; Stack, M.S.
Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity
Histol. Histopathol.
24
197-207
2009
Homo sapiens
brenda
Brattsand, M.; Stefansson, K.; Hubiche, T.; Nilsson, S.K.; Egelrud, T.
SPINK9: A selective, skin-specific Kazal-type serine protease inhibitor
J. Invest. Dermatol.
129
1656-1665
2009
Homo sapiens
brenda
Meyer-Hoffert, U.; Wu, Z.; Schroeder, J.M.
Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor
PLoS ONE
4
e4372
2009
Homo sapiens
brenda
Mavridis, K.; Talieri, M.; Scorilas, A.
KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone
Biol. Chem.
391
467-474
2010
Homo sapiens (Q9Y337)
brenda
Li, X.; Liu, J.; Wang, Y.; Zhang, L.; Ning, L.; Feng, Y.
Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies
Cancer Sci.
100
601-607
2009
Homo sapiens
brenda
Briot, A.; Deraison, C.; Lacroix, M.; Bonnart, C.; Robin, A.; Besson, C.; Dubus, P.; Hovnanian, A.
Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome
J. Exp. Med.
206
1135-1147
2009
Mus musculus (Q9D140), Mus musculus
brenda
Teixeira, T.S.; Freitas, R.F.; Abrahao, O.; Devienne, K.F.; de Souza, L.R.; Blaber, S.I.; Blaber, M.; Kondo, M.Y.; Juliano, M.A.; Juliano, L.; Puzer, L.
Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7
Bioorg. Med. Chem. Lett.
21
6112-6115
2011
Homo sapiens
brenda
Britland, S.; Hoyle, M.
Transcriptional gene silencing of kallikrein 5 and kallikrein 7 using siRNA prevents epithelial cell detachment induced by alkaline shock in an in vitro model of eczema
Biotechnol. Prog.
28
485-489
2011
Homo sapiens
brenda
Jiang, R.; Shi, Z.; Johnson, J.J.; Liu, Y.; Stack, M.S.
Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma
J. Biol. Chem.
286
9127-9135
2011
Homo sapiens
brenda
De Souza, L.; M. Melo, P.; Paschoalin, T.; Carmona, A.; Kondo, M.; Hirata, I.; Blaber, M.; Tersariol, I.; Takatsuka, J.; Juliano, M.; Juliano, L.; Gomes, R.; Puzer, L.
Human tissue kallikreins 3 and 5 can act as plasminogen activator releasing active plasmin
Biochem. Biophys. Res. Commun.
433
333-337
2013
Homo sapiens (Q9Y337)
brenda
Sakabe, J.; Yamamoto, M.; Hirakawa, S.; Motoyama, A.; Ohta, I.; Tatsuno, K.; Ito, T.; Kabashima, K.; Hibino, T.; Tokura, Y.
Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes
J. Biol. Chem.
288
17179-17189
2013
Homo sapiens (Q9Y337), Homo sapiens
brenda
Santos, J.A.; Kondo, M.Y.; Freitas, R.F.; dos Santos, M.H.; Ramalho, T.C.; Assis, D.M.; Juliano, L.; Juliano, M.A.; Puzer, L.
The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins
Bioorg. Med. Chem. Lett.
26
1485-1489
2016
Homo sapiens
brenda
White, G.V.; Edgar, E.V.; Holmes, D.S.; Lewell, X.Q.; Liddle, J.; Polyakova, O.; Smith, K.J.; Thorpe, J.H.; Walker, A.L.; Wang, Y.; Young, R.J.; Hovnanian, A.
Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome
Bioorg. Med. Chem. Lett.
29
821-825
2019
Homo sapiens (Q9Y337)
brenda
Hoelz, L.V.B.; Zorzanelli, B.C.; Azevedo, P.H.R.A.; Passos, S.G.; de Souza, L.R.; Zani, M.; Pinheiro, S.; Puzer, L.; Dias, L.R.S.; Muri, E.M.F.
Synthesis, biological evaluation and molecular modeling of pseudo-peptides based statine as inhibitors for human tissue kallikrein 5
Eur. J. Med. Chem.
112
39-47
2016
Homo sapiens (Q9Y337), Homo sapiens
brenda
Andoh, T.; Tsujii, K.; Kuraishi, Y.
Increase in pruritogenic kallikrein 5 in the skin of NC mice with chronic dermatitis
Exp. Dermatol.
24
978-980
2015
Mus musculus (P15945)
brenda
Yang, F.; Li, J.Y.; Yin, Q.N.; Yang, K.; Dong, S.N.; Bai, L.J.; Liu, P.; Tong, X.W.
Human kallikrein 5 as a novel prognostic biomarker for triple-negative breast cancer tissue expression analysis and relationship with disease course
Genet. Mol. Res.
14
9655-9666
2015
Homo sapiens (Q9Y337), Homo sapiens
brenda
Cartner, T.; Brand, N.; Tian, K.; Saud, A.; Carr, T.; Stapleton, P.; Lane, M.E.; Rawlings, A.V.
Effect of different alcohols on stratum corneum kallikrein 5 and phospholipase A2 together with epidermal keratinocytes and skin irritation
Int. J. Cosmet. Sci.
39
188-196
2017
Homo sapiens (Q9Y337)
brenda
Jang, H.; Matsuda, A.; Jung, K.; Karasawa, K.; Matsuda, K.; Oida, K.; Ishizaka, S.; Ahn, G.; Amagai, Y.; Moon, C.; Kim, S.H.; Arkwright, P.D.; Takamori, K.; Matsuda, H.; Tanaka, A.
Skin pH is the master switch of kallikrein 5-mediated skin barrier destruction in a murine atopic dermatitis model
J. Invest. Dermatol.
136
127-135
2016
Mus musculus (P15945), Mus musculus
brenda
Walker, A.L.; Denis, A.; Bingham, R.P.; Bouillot, A.; Edgar, E.V.; Ferrie, A.; Holmes, D.S.; Laroze, A.; Liddle, J.; Fouchet, M.H.; Moquette, A.; Nassau, P.; Pearce, A.C.; Polyakova, O.; Smith, K.J.; Thomas, P.; Thorpe, J.H.; Trottet, L.; Wang, Y.; Hovnanian, A.
Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors
Bioorg. Med. Chem. Lett.
29
126675
2019
Homo sapiens (Q9Y337)
brenda
Di Paolo, C.T.; Filippou, P.S.; Yu, Y.; Poda, G.; Diamandis, E.P.; Prassas, I.
Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses
Clin. Chem. Lab. Med.
57
1737-1743
2019
Homo sapiens (Q9Y337)
brenda
Lenga Ma Bonda, W.; Lavergne, M.; Vasseur, V.; Brisson, L.; Roger, S.; Legras, A.; Guillon, A.; Guyetant, S.; Hiemstra, P.S.; Si-Tahar, M.; Iochmann, S.; Reverdiau, P.
Kallikrein-related peptidase 5 contributes to the remodeling and repair of bronchial epithelium
FASEB J.
35
e21838
2021
Homo sapiens (Q9Y337)
brenda
Ortloff, A.; Bustamante, F.A.; Molina, L.; Ojeda, J.; Figueroa, C.D.; Ehrenfeld, P.
Kallikrein-related peptidase 5 (KLK5) expression and distribution in canine cutaneous squamous cell carcinoma
J. Comp. Pathol.
174
113-119
2020
Canis lupus familiaris
brenda
Gonschorek, P.; Zorzi, A.; Maric, T.; Le Jeune, M.; Schuettel, M.; Montagnon, M.; Gomez-Ojea, R.; Vollmar, D.P.; Whitfield, C.; Reymond, L.; Carle, V.; Verma, H.; Schilling, O.; Hovnanian, A.; Heinis, C.
Phage display selected cyclic peptide inhibitors of kallikrein-related peptidases 5 and 7 and their in vivo delivery to the skin
J. Med. Chem.
65
9735-9749
2022
Homo sapiens (Q9Y337)
brenda
Ma, H.; Hockla, A.; Mehner, C.; Coban, M.; Papo, N.; Radisky, D.C.; Radisky, E.S.
PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma
Sci. Rep.
9
1844
2019
Homo sapiens (Q9Y337)
brenda
EXTERNAL LINKS (specific for EC-Number 3.4.21.B39)
html completed
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2026.1 (March 2026)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
![DSMZ Digital Diversity]()
![Global Core Biodata Resource]()
![ELIXIR Core Data Resource]()
![German Network for Bioinformatics Infrastructure]()
